Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center | Zendy

Vijay Patil | Zendy; Arun Chandrasekharan | Zendy; Dilip Harindran Vallathol | Zendy; Mridul Malhotra | Zendy; Ram Abhinav | Zendy; Priti Agarwal | Zendy; Anu Rajpurohit | Zendy; Raees Tonse | Zendy; Atanu Bhattacharjee | Zendy; Rakesh Jalali | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center

Author(s) -

Vijay Patil,

Arun Chandrasekharan,

Dilip Harindran Vallathol,

Mridul Malhotra,

Ram Abhinav,

Priti Agarwal,

Anu Rajpurohit,

Raees Tonse,

Atanu Bhattacharjee,

Rakesh Jalali

Publication year - 2019

Publication title -

neuro-oncology practice

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 14

eISSN - 2054-2585

pISSN - 2054-2577

DOI - 10.1093/nop/npz009

Subject(s) - ondansetron , nausea , medicine , antiemetic , olanzapine , vomiting , anesthesia , domperidone , schizophrenia (object oriented programming) , psychiatry , dopamine

In our previous experience, a significant proportion of patients who received 5-HT 3 antagonist monotherapy with adjuvant temozolomide (150-200 mg/m 2 ) had chemotherapy-induced nausea and vomiting (CINV). This is an audit comparing the multiple antiemetic therapies in the prevention of temozolomide-associated CINV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research